Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705546 | 1.00 | NFE2L2 (0.55) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL20640997 | 0.85 | NFE2L2 (0.52) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL5265029 | 0.84 | NFE2L2 (0.55) | NFE2L2ALDH1A1CYP3A4RECQLPTGS1 | |
| SCHEMBL22418163 | 0.81 | PKM (0.37) | NFE2L2ALDH1A1CYP3A4RECQLBACE1 | |
| SCHEMBL14604965 | 0.80 | NFE2L2 (0.55) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL704660 | 0.80 | NFE2L2 (0.55) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL704659 | 0.80 | NFE2L2 (0.55) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL5541438 | 0.78 | NFE2L2 (0.53) | NFE2L2CES2CES1CA3CA6 | |
| SCHEMBL28591692 | 0.77 | PTGS1 (0.42) | NFE2L2ALDH1A1CYP3A4RECQLPTGS1 | |
| SCHEMBL5970809 | 0.77 | P4HB (0.37) | NFE2L2CA3CA6CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8193179-B2 | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-06-05 | — | — | US | disclosed |
| WO-2012040321-A3 | METHODS AND APPARATUS FOR EHNANCED GAS DISTRIBUTION | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| EP-1981881-B1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-2167494-B1 | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110071155-A1 | Tricyclic Nitrogen Containing Compounds And Their Use As Antibacterials | GLAXO GROUP LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| EP-1981881-A1 | TETRAHYDROPYRANE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007086016-A1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| CN-1795191-A | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2006-06-28 | — | — | CN | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | HRH2, HRH1, HRH3 | NFE2L2 788/4885CES2 260/4885CES1 1189/4885 |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NFE2L2 1804/4885CES2 2890/4885CES1 3688/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | NFE2L2 1804/4885CES2 2890/4885CES1 3688/4885 |
| US-20110071155-A1 | Tricyclic Nitrogen Containing Compounds And Their Use As Antibacterials | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYCS | NFE2L2 1557/4885CES2 286/4885CES1 493/4885 |
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | NFE2L2 1466/4885CES2 14/4885CES1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.